Press Releases

« Back to news

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 17, 2022 at 8:30 AM EDT

LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Tuesday, May 24, 2022.

A webcast of the presentation will be made available on the Investors section of the company's website at The webcast replay will be available for approximately 30 days.

About LogicBio® Therapeutics 

LogicBio® Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide®, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company's proprietary system, mAAVRx™, aims to overcome some of the current limitations of AAV manufacturing by optimizing the transfection process to improve yields and product quality. The company is based in Lexington, MA. For more information, visit, which does not form a part of this release.

Investor Contacts: 
Stephen Jasper
Gilmartin Group

Media Contacts:
Adam Daley
Berry & Company Public Relations
C: 614-580-2048

Cision View original content:

SOURCE LogicBio Therapeutics, Inc.